Figure 2

Increased CRF levels in the amygdala but not in other brain regions in GluN2B-YF mice. (A)-(D) Real-time PCR analyses showed that CRF mRNA levels were increased in the amygdala (WT, n = 5; YF, n = 5; p < 0.05, Student's t-test) (A) but not in other brain regions, including the hippocampus (WT, n = 5; YF, n = 5; p > 0.2, Student's t-test) (B), cerebellum (WT, n = 5; YF, n = 5; p > 0.2, Student's t-test) (C), and hypothalamus (WT, n = 5; YF, n = 5; p > 0.5, Student's t-test) (D), of GluN2B-YF mice compared to WT mice. (E) Increased expression of CRF in the amygdala was confirmed by ELISA (WT, n = 10; YF, n = 10; p < 0.01, Student's t-test). (F) The plasma ACTH level of GluN2B-YF mice was not significantly different from that of WT mice (WT, n = 9; YF, n = 13; p > 0.5, Student's t-test). The asterisk indicates significant genotype differences. n.s., not significant.